🚨 Why HIMS Is Everywhere Right Now

Hims & Hers Health (HIMS) has been one of 2025’s most talked-about stocks — and one of its most unpredictable.

In just a few months, shares have soared past $70, collapsed to $25, then rebounded above $50. Behind the scenes? Explosive growth in subscribers, a red-hot weight loss drug market, and a ton of retail hype.

But with short sellers circling and analysts split, the question for investors is simple:

Is HIMS just getting started — or is this house of health ready to fall?

📊 The Big Picture: What’s Driving the Stock?

  • Wild Swings:
    Started the year near $25 → Shot past $70 → Dipped back to $25 → Now over $52
    That’s a 120%+ gain year-to-date, despite serious turbulence.

  • Real Growth:
    Revenue hit $586M in Q1, up sharply year-over-year
    Net income up 345%
    Subscribers: 2.4M+, up nearly 40%

  • The Weight Loss Factor:
    Nearly 40% of revenue now comes from GLP-1 drugs like Wegovy, thanks to a partnership with Novo Nordisk
    That’s fueling momentum — but also creating dependence

  • Fundamentals Still Look Solid:
    HIMS is growing revenue at 100%+ YoY, has $300M in cash, zero debt, and trades at just 6.8x sales.
    For comparison: Palantir trades at 72x, Duolingo at 22x, Robinhood at 17x.
    For a high-growth company with this trajectory — that’s cheap./

  • Not Just "Pills for Men":
    HIMS is becoming a personalized medicine platform: mental health, dermatology, hormone support, sleep treatment, at-home tests.
    And they’re not doing it alone — they’ve partnered with giants like Novo Nordisk and Eli Lilly.

If current momentum holds, today’s price could be just the beginning.

🧠 Wall Street Can’t Agree

  • Mixed Ratings:
    Most analysts call it a “Hold.”
    Average price target? $38 — well below today’s price
    Some top banks (BofA, Citi) call it a “Sell” with targets near $28–$30

  • Short Sellers Are Swarming:
    HIMS is now the most-shorted stock in the S&P MidCap 400
    Over 34% short interest — meaning many big players expect the stock to fall hard

  • But Bulls Are Holding On:
    Some models forecast $59.55 by July
    Management is aiming for $6B in revenue by 2030 — a bold target based on telehealth expansion

🚩 What to Watch (and Worry About)

  1. GLP-1 Supply Chain
    The FDA banned compounded versions this year, forcing HIMS to rely on drugmakers. That could squeeze margins or slow growth.

  2. High Marketing Spend
    HIMS spends nearly 40% of revenue on ads. Great when growth is fast. Risky when it slows.

  3. Retail Volatility
    After listing in South Korea, the stock got flooded with retail money — making swings more frequent (and more dangerous).

  4. Regulatory Heat
    The telehealth boom is still young. Fast scaling + health products = possible legal headaches.

💼 What This Means for You

  • If You’re Tempted to Buy In:

    • Know that HIMS is a high-risk, high-reward bet — not a sleep-easy investment

    • Growth is real, but heavily tied to GLP-1 hype

    • A short squeeze is possible, but timing that is a gamble

  • If You Already Own It:

    • Ask: has this grown too big a piece of your portfolio?

    • Consider locking in gains or trimming if you're near retirement

    • Stay informed: any bad FDA news or earnings miss could move this stock fast

✅ Takeaway: This Isn’t a “Set It and Forget It” Stock

HIMS has all the markings of a modern-day disruptor — and all the volatility that comes with it.

If you believe in telehealth’s future, it might belong on your watchlist.
But if you’re looking for steady growth or sleep-at-night safety? There are safer places to park your cash.

Bottom line:
HIMS is booming — but still bumpy. And for some, it may already feel like a bubble.

🧠 One of Us Is In — And Still Holding

For full transparency:
One of our team members bought $500 worth of HIMS stock in early January 2025 at $25/share.

That’s 20 shares.
At today’s price of $52, that investment is now worth:

20 shares × $52 = $1,040
📈 That’s more than double — a +108% gain in less than 6 months.

“I’m still holding. It’s a rollercoaster, but I believe HIMS has room to grow. And I’m watching every earnings call like a hawk.”
— T.I.M. Team Member

We’re not giving investment advice.
But we are showing you we put skin in the game — and we’re watching this story unfold, just like you.

Keep Reading